Radioactive 'Smart Bomb' targets Hard-to-Treat breast cancer
NCT ID NCT04529044
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing a radioactive drug called 177Lu-DOTATATE in 10 people with stage IV or recurrent breast cancer. The drug seeks out cancer cells that have a specific receptor (SSTR2) and delivers radiation to kill them. The goal is to see if it can shrink tumors and reduce cancer stem cells in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-DOTATATE (a radioactive drug that targets tumor cells with SSTR2)
What this could lead to
If it works, this could offer a new treatment option for people with advanced breast cancer that has a specific marker (SSTR2).
What could go wrong
This is a very small, early-phase pilot study with only 10 participants, so results may not apply to everyone. The treatment involves radiation, which can cause side effects, and it may not shrink tumors in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact